• 1
    Noldus J, Stamey TA. Histological characteristics of radical prostatectomy specimens in men with a serum prostate specific antigen of 4 ng./ml. or less. J. Urol. 1996; 155: 4413.
  • 2
    Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6–4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277: 14525.
  • 3
    Lodding P, Aus G, Bergdahl S et al. Characteristics of screening detected prostate cancer in men 50–66 years old with 3–4 ng/ml prostate specific antigen. J. Urol. 1998; 159: 899903.
  • 4
    Schröder FH, Van Der Cruijsen-Koeter I, De Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J. Urol. 2000; 163: 80612.
  • 5
    Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamker VA, Fritsche HA Jr. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml relation to biopsy strategy. J. Urol. 2001; 165: 75760.
  • 6
    Krumholtz JS, Carvalhal GF, Ramos CG et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002; 60: 46974.
  • 7
    Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993; 71: 203140.
  • 8
    Lee WR, Hanks GE, Corn BW, Schultheiss TE. Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy. Int. J. Radiat. Oncol. Biol. Phys 1995; 31: 214.
  • 9
    Goluboff ET, Heitjan DF, DeVries GM, Katz AE, Benson MC, Olsson CA. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J. Urol. 1997; 158: 18769.
  • 10
    Nam RK, Klotz LH, Jewett MAS, Danjoux C, Trachtenberg J. Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a ‘rapid riser’ subset. Br. J. Urol. 1998; 81: 100104.
  • 11
    Gerber GS, Gornik HL, Goldfischer ER, Chodak GW, Rukstalis DB. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy. J. Urol. 1998; 159: 12436.
  • 12
    McLaren DB, McKenzie M, Duncan G, Pickles T. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1998; 82: 3428.
  • 13
    Egawa S, Matsumoto K, Suyama K, Iwamura M, Kuwao S, Baba S. Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma. Cancer 1999; 86: 4639.
  • 14
    Egawa S, Arai Y, Tobisu K et al. Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis. 2000; 3: 26974.
  • 15
    Stephenson AJ, Aprikian AG, Souhami L et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 2002; 59: 6526.
  • 16
    Kakehi Y, Kamoto T, Shiraishi T et al. Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men. Eur. Urol. 2002; 41: 4753.
  • 17
    Choo R, Klotz L, Danjoux C et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J. Urol. 2002; 167: 16649.
  • 18
    Ito K, Yamamoto T, Ohi M et al. Natural history of PSA increase with and without prostate cancer. Urology 2003; 62: 649.
  • 19
    Carter HB, Morrell CH, Pearson JD et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostatic disease. Cancer Res. 1992; 52: 33238.
  • 20
    Whittemore AS, Lele C, Friedman GD, Stamey T, Vogelman JH, Orentreich N. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J. Natl. Cancer Inst. 1995; 87: 35460.